



WHAT IS CLAIMED IS:


1. A compound of the formula:




in which R is represented by hydrogen, halogen, C_{1-4} alkyl, C_{1-4} alkoxy, $-CF_3$, $-OH$, or $-OCF_3$; and A is represented by one of the following imide derivatives:




Ia




Ie




Ib




If




Ic



Ig



Id



Ih

in which R_1 and R_2 are each independently represented by hydrogen, halogen, C_{1-4} alkyl, C_{1-4} alkoxy, $-CF_3$, $-OH$, or $-OCF_3$; and the pharmaceutically acceptable salts thereof.

2. A compound according to claim 1 in which R is a para-halogen substituent.

3. A compound according to claim 2 in which R is a fluorine.

4. A method for the treatment of thrombotic illness comprising the administration of a compound according to claim 1 in an antithrombotic amount to a patient in need thereof.

5. A method for the treatment of angina comprising administering to a patient in need thereof an anti-anginal amount of a compound according to claim 1.

6. A method for the treatment of anorexia nervosa comprising administering to a patient in need thereof an anti-anorexic amount of a compound according to claim 1.

7. A method for the treatment of Raynaud's phenomenon comprising administering to a patient in need thereof a compound according to claim 1 in an amount sufficient to relieve or alleviate the patient's symptomatology.

8. A method for the treatment of coronary vasospasms comprising administering to a patient in need thereof an anti-spasmodic amount of a compound according to claim 1.

9. A method for the treatment fibromyalgia comprising administering to a patient in need thereof an anti-fibromyalgia amount of a compound according to claim 1.

10. A method for the treatment of the extra-pyramidal side effects associated with neuroleptic therapy comprising administering to a patient in need thereof an anti-EPS amount of a compound according to claim 1.

11. A method for relieving or alleviating anxiety

comprising administering to a patient in need thereof, an anxiolytic amount of a compound according to claim 1.

12. A composition comprising a compound according to claim 1 in admixture with an inert carrier.

13. A composition according to claim 11 wherein said inert carrier is a pharmaceutical carrier.

14. A composition according to claim 11 which contains a thromboxane synthetase inhibitor.

15. A method for antagonizing the effects of serotonin at the 5HT₂ receptor comprising administering a compound according to claim 1 to a patient in need thereof.

16. A method for the treatment of drug abuse comprising administering a compound according to claim 1 to a patient in need thereof.

17. A method for the treatment of psychosis comprising administering a compound according to claim 1 to a patient in need thereof.

18. A method for the treatment of glaucoma comprising administering a compound according to claim 1 to a patient in need thereof.